Nanomaterials-Based Electrochemical Δ9-THC and CBD Sensors for Chronic Pain
- PMID: 36979596
- PMCID: PMC10046734
- DOI: 10.3390/bios13030384
Nanomaterials-Based Electrochemical Δ9-THC and CBD Sensors for Chronic Pain
Abstract
Chronic pain is now included in the designation of chronic diseases, such as cancer, diabetes, and cardiovascular disease, which can impair quality of life and are major causes of death and disability worldwide. Pain can be treated using cannabinoids such as Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) due to their wide range of therapeutic benefits, particularly as sedatives, analgesics, neuroprotective agents, or anti-cancer medicines. While little is known about the pharmacokinetics of these compounds, there is increasing interest in the scientific understanding of the benefits and clinical applications of cannabinoids. In this review, we study the use of nanomaterial-based electrochemical sensing for detecting Δ9-THC and CBD. We investigate how nanomaterials can be functionalized to obtain highly sensitive and selective electrochemical sensors for detecting Δ9-THC and CBD. Additionally, we discuss the impacts of sensor pretreatment at fixed potentials and physiochemical parameters of the sensing medium, such as pH, on the electrochemical performance of Δ9-THC and CBD sensors. We believe this review will serve as a guideline for developing Δ9-THC and CBD electrochemical sensors for point-of-care applications.
Keywords: cancer painkiller; cannabinoids; chronic diseases; electrochemical sensing; functionalization; nanomaterials.
Conflict of interest statement
The authors declare no conflict of interest.
Figures






Similar articles
-
Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.Front Biosci (Landmark Ed). 2022 Jul 25;27(8):228. doi: 10.31083/j.fbl2708228. Front Biosci (Landmark Ed). 2022. PMID: 36042166
-
Cannabinoids in Oral Fluid: Limiting Potential Sources of Cannabidiol Conversion to Δ9- and Δ8-Tetrahydrocannabinol.J Anal Toxicol. 2021 Sep 17;45(8):807-812. doi: 10.1093/jat/bkab074. J Anal Toxicol. 2021. PMID: 34137890
-
Quantitation of Δ8-THC, Δ9-THC, Cannabidiol and 10 Other Cannabinoids and Metabolites in Oral Fluid by HPLC-MS-MS.J Anal Toxicol. 2022 Feb 14;46(1):76-88. doi: 10.1093/jat/bkaa184. J Anal Toxicol. 2022. PMID: 33270860
-
A crowdsourcing survey study on the subjective effects of delta-8-tetrahydrocannabinol relative to delta-9-tetrahydrocannabinol and cannabidiol.Exp Clin Psychopharmacol. 2023 Apr;31(2):312-317. doi: 10.1037/pha0000565. Epub 2022 Apr 25. Exp Clin Psychopharmacol. 2023. PMID: 35467921
-
A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment.Molecules. 2020 Oct 25;25(21):4930. doi: 10.3390/molecules25214930. Molecules. 2020. PMID: 33113776 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical